Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor

OBJECTIVES: Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, JNJ-54861911, were assessed after single and multiple dosing in healthy participants. METHODS: Two randomized, placebo-controlled, double-blind st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Dement (N Y)
Main Authors: Timmers, Maarten, Van Broeck, Bianca, Ramael, Steven, Slemmon, John, De Waepenaert, Katja, Russu, Alberto, Bogert, Jennifer, Stieltjes, Hans, Shaw, Leslie M., Engelborghs, Sebastiaan, Moechars, Dieder, Mercken, Marc, Liu, Enchi, Sinha, Vikash, Kemp, John, Van Nueten, Luc, Tritsmans, Luc, Streffer, Johannes Rolf
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2016
Assuntos:
Featured Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651349/
https://ncbi.nlm.nih.gov/pubmed/29067308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2016.08.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados